{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GW642444+25",
    "query": {
      "intervention": "GW642444 25"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 15,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GW642444+25&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-15T18:57:57.992Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01316887",
      "title": "A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "125/25 mcg once-daily GSK573719/GW642444",
          "type": "DRUG"
        },
        {
          "name": "125mcg once-daily GSK573719",
          "type": "DRUG"
        },
        {
          "name": "Placebo once-daily",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "40 Years to 120 Years"
      },
      "enrollment_count": 563,
      "start_date": "2011-01-01",
      "completion_date": "2012-07-21",
      "has_results": true,
      "last_update_posted_date": "2018-05-02",
      "last_synced_at": "2026-09-15T18:57:57.992Z",
      "location_count": 15,
      "location_summary": "Mobile, Alabama • Sunset, Louisiana • Plymouth, Minnesota + 12 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Sunset",
          "state": "Louisiana"
        },
        {
          "city": "Plymouth",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01316887"
    },
    {
      "nct_id": "NCT03248128",
      "title": "Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "FF/VI via ELLIPTA DPI",
          "type": "DRUG"
        },
        {
          "name": "FF via ELLIPTA DPI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 906,
      "start_date": "2017-10-20",
      "completion_date": "2022-03-21",
      "has_results": true,
      "last_update_posted_date": "2025-06-22",
      "last_synced_at": "2026-09-15T18:57:57.992Z",
      "location_count": 49,
      "location_summary": "Hoover, Alabama • Little Rock, Arkansas • Huntington Beach, California + 38 more",
      "locations": [
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03248128"
    },
    {
      "nct_id": "NCT01323660",
      "title": "An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "GSK573719/GW642444 125/25",
          "type": "DRUG"
        },
        {
          "name": "GSK573719/GW642444 62.5/25",
          "type": "DRUG"
        },
        {
          "name": "GSK573719 125",
          "type": "DRUG"
        },
        {
          "name": "GSK573719 62.5",
          "type": "DRUG"
        },
        {
          "name": "GW642444 25",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "40 Years and older · Male only"
      },
      "enrollment_count": 307,
      "start_date": "2011-03-16",
      "completion_date": "2012-07-16",
      "has_results": true,
      "last_update_posted_date": "2018-02-15",
      "last_synced_at": "2026-09-15T18:57:57.992Z",
      "location_count": 18,
      "location_summary": "Jasper, Alabama • Torrance, California • Fort Collins, Colorado + 15 more",
      "locations": [
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01323660"
    },
    {
      "nct_id": "NCT01817764",
      "title": "A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Umeclidinium/vilanterol",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone propionate/salmeterol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 707,
      "start_date": "2013-03-01",
      "completion_date": "2013-10-25",
      "has_results": true,
      "last_update_posted_date": "2017-11-08",
      "last_synced_at": "2026-09-15T18:57:57.992Z",
      "location_count": 9,
      "location_summary": "Jasper, Alabama • Phoenix, Arizona • San Diego, California + 6 more",
      "locations": [
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01817764"
    },
    {
      "nct_id": "NCT01894386",
      "title": "Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "FF 400 mcg",
          "type": "DRUG"
        },
        {
          "name": "UMEC 500 mcg",
          "type": "DRUG"
        },
        {
          "name": "UMEC 250 mcg",
          "type": "DRUG"
        },
        {
          "name": "VI 100 mcg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 48,
      "start_date": "2013-07-15",
      "completion_date": "2013-09-26",
      "has_results": false,
      "last_update_posted_date": "2017-05-15",
      "last_synced_at": "2026-09-15T18:57:57.992Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01894386"
    },
    {
      "nct_id": "NCT01453296",
      "title": "Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "GW642444",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "5 Years to 11 Years"
      },
      "enrollment_count": 28,
      "start_date": "2010-08",
      "completion_date": "2011-04",
      "has_results": true,
      "last_update_posted_date": "2017-01-13",
      "last_synced_at": "2026-09-15T18:57:57.992Z",
      "location_count": 5,
      "location_summary": "Cypress, California • Huntington Beach, California • Denver, Colorado + 2 more",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Normal",
          "state": "Illinois"
        },
        {
          "city": "Medford",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01453296"
    },
    {
      "nct_id": "NCT01323634",
      "title": "Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Propionate 250mcg/ salmeterol 50mcg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 519,
      "start_date": "2011-03-18",
      "completion_date": "2011-12-14",
      "has_results": true,
      "last_update_posted_date": "2017-11-08",
      "last_synced_at": "2026-09-15T18:57:57.992Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Orlando, Florida • Atlanta, Georgia + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Madisonville",
          "state": "Kentucky"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01323634"
    },
    {
      "nct_id": "NCT01009463",
      "title": "A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "FF/GW642444 Inhalation Powder",
          "type": "DRUG"
        },
        {
          "name": "GW642444 Inhalation Powder",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 1626,
      "start_date": "2009-09-25",
      "completion_date": "2011-10-31",
      "has_results": true,
      "last_update_posted_date": "2017-11-09",
      "last_synced_at": "2026-09-15T18:57:57.992Z",
      "location_count": 94,
      "location_summary": "Birmingham, Alabama • Jasper, Alabama • Peoria, Arizona + 85 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01009463"
    },
    {
      "nct_id": "NCT01316913",
      "title": "24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "GSK573719/GW642444 125/25",
          "type": "DRUG"
        },
        {
          "name": "GSK573719/GW642444 62.5/25",
          "type": "DRUG"
        },
        {
          "name": "GSK573719",
          "type": "DRUG"
        },
        {
          "name": "tiotropium bromide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 872,
      "start_date": "2011-03",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2017-04-04",
      "last_synced_at": "2026-09-15T18:57:57.992Z",
      "location_count": 20,
      "location_summary": "Jasper, Alabama • Mobile, Alabama • Huntington Beach, California + 17 more",
      "locations": [
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01316913"
    },
    {
      "nct_id": "NCT01879410",
      "title": "A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI",
          "type": "DRUG"
        },
        {
          "name": "FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS",
          "type": "DRUG"
        },
        {
          "name": "Placebo DISKUS",
          "type": "DRUG"
        },
        {
          "name": "Placebo NDPI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 700,
      "start_date": "2013-06-13",
      "completion_date": "2014-01-09",
      "has_results": true,
      "last_update_posted_date": "2017-11-08",
      "last_synced_at": "2026-09-15T18:57:57.992Z",
      "location_count": 15,
      "location_summary": "Tucson, Arizona • Newport Beach, California • Riverside, California + 12 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Coeur d'Alene",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01879410"
    }
  ]
}